GlassScriptPhysician profile
Leonard Haas
NPI 1073019584
$2,521.98
in general payments reported to CMS, 2019-2025
17 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 86% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $154 · 2024: $460 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $967.79 | 2024-2025 | Tremfya, Stelara |
| Mirum Pharmaceuticals, INC. | $442.19 | 2023-2025 | Livmarli |
| Genzyme Corporation | $169.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.78 | 2025 | Eohilia, Entyvio |
| Madrigal Pharmaceuticals | $150.86 | 2024-2025 | Resmetirom, Rezdiffra |
| Celltrion USA INC. | $139.86 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $104.03 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $91.99 | 2025 | Vowst |
| Abbvie INC. | $82.17 | 2024-2025 | |
| Braintree Laboratories, INC. | $37.20 | 2025 | Sutab, Suflave |
| Novo Nordisk INC | $35.44 | 2024-2025 | Wegovy |
| Regeneron Pharmaceuticals, INC. | $33.07 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $25.83 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $21.89 | 2025 | Iqirvo |
| Exact Sciences Corporation | $20.33 | 2024 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $19.30 | 2024 | Sucraid |
| Evoke Pharma, INC. | $17.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.